{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["7(2)"],"submitter":["Huet F"],"pubmed_abstract":["Aims
Biomarkers are not recommended until now to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. The current study considered pre-discharged sST2 values as a guide for medical management in patients admitted for acute HF decompensation, in an attempt to reduce hospital readmission.Methods and results
STADE-HF was a blinded prospective randomized controlled trial and included 123 patients admitted for acute HF. They were randomized into the usual treatment group (unknown sST2 level) or the interventional treatment group, for whom sST2 level was known and used on Day 4 of hospitalization to guide the treatment. The primary endpoint was the readmission rate for any cause at 1 month. It o"],"journal":["ESC heart failure"],"pagination":["774-778"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7160465"],"repository":["biostudies-literature"],"pubmed_title":["STADE-HF (sST2 As a help for management of HF): a pilot study."],"pmcid":["PMC7160465"],"pubmed_authors":["Kalmanovich E","Breuker C","Castet-Nicolas A","Roubille F","Pasquie JL","Roubille C","Bourel G","Curinier C","Mercier G","Lotierzo M","Akodad M","Adda J","Leclercq F","Zerkowski L","Fesler P","Cristol JP","Agullo A","Dupuy AM","Nicoleau J","Battistella P","Huet F"],"additional_accession":[]},"is_claimable":false,"name":"STADE-HF (sST2 As a help for management of HF): a pilot study.","description":"Aims
Biomarkers are not recommended until now to guide the management of patients with heart failure (HF). Soluble suppression of tumorigenicity 2 (sST2) appears as a promising biomarker. The current study considered pre-discharged sST2 values as a guide for medical management in patients admitted for acute HF decompensation, in an attempt to reduce hospital readmission.Methods and results
STADE-HF was a blinded prospective randomized controlled trial and included 123 patients admitted for acute HF. They were randomized into the usual treatment group (unknown sST2 level) or the interventional treatment group, for whom sST2 level was known and used on Day 4 of hospitalization to guide the treatment. The primary endpoint was the readmission rate for any cause at 1 month. It o","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Apr","modification":"2025-04-04T22:34:33.171Z","creation":"2020-05-22T17:35:26Z"},"accession":"S-EPMC7160465","cross_references":{"pubmed":["32168423"],"doi":["10.1002/ehf2.12663"]}}